Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000279253 | SCV000342509 | uncertain significance | not provided | 2016-06-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000279253 | SCV001785409 | likely benign | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Labcorp Genetics |
RCV002059236 | SCV002430175 | benign | X-linked myopathy with postural muscle atrophy | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001699283 | SCV004223180 | likely benign | not specified | 2023-11-27 | criteria provided, single submitter | clinical testing | Variant summary: FHL1 c.889-9delT alters a non-conserved nucleotide located at a position not widely known to affect splicing. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The frequency data for this variant in gnomAD is considered unreliable, as metrics indicate poor data quality at this position. To our knowledge, no occurrence of c.889-9delT in individuals affected with Emery-Dreifuss Muscular Dystrophy and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, and classified it as benign (n=1), likely benign (n=1), or uncertain significance (n=1). Based on the evidence outlined above, the variant was classified as likely benign. |
Clinical Genetics, |
RCV001699283 | SCV001921879 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001699283 | SCV001967078 | benign | not specified | no assertion criteria provided | clinical testing |